3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
103
Lymphoma
68
Lymphoma, Large B-Cell, Diffuse
49
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Sarcoma
33
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Leukemia
23
Burkitt Lymphoma
22
Neoplasms
19
Lymphoma, Mantle-Cell
18
Triple Negative Breast Neoplasms
15
Multiple Myeloma
15
Lymphoma, Follicular
15
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Anaplastic
12
Carcinoma, Hepatocellular
12
Breast Neoplasms, Male
11
Neuroblastoma
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Inflammatory Breast Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, T-Cell
8
Osteosarcoma
7
Fallopian Tube Neoplasms
7
Urinary Bladder Neoplasms
6
Liposarcoma
6
Interventions
Leucovorin
38
Fluorouracil
36
Oxaliplatin
34
Bevacizumab
34
Irinotecan
32
Cetuximab
23
Capecitabine
18
Panitumumab
14
IFL protocol
7
Folfox protocol
6
Celecoxib
6
Radiotherapy
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gene Expression Profiling
5
regorafenib
4
pembrolizumab
4
dehydroftorafur
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
aflibercept
3
Surgical Procedures, Operative
3
Sorafenib
3
Radiosurgery
3
Ipilimumab
3
Gemcitabine
3
Fentanyl
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colonic Neoplasms
×
Doxorubicin
×
Clear all
NCT01464593
2022-10-13
ABLATE
Imunon
Phase 2
Terminated
2 enrolled
5 charts